Omnicell, Inc. (OMCL)

US — Healthcare Sector
Peers: PGNY  SDGR  OMDA  TDOC  TXG  PHR  UFPT  ASTH  SSII  GDRX 

Automate Your Wheel Strategy on OMCL

With Tiblio's Option Bot, you can configure your own wheel strategy including OMCL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol OMCL
  • Rev/Share 25.435
  • Book/Share 26.3671
  • PB 1.4074
  • Debt/Equity 0.1596
  • CurrentRatio 1.4447
  • ROIC 0.0067

 

  • MktCap 1718743638.0
  • FreeCF/Share 2.4073
  • PFCF 15.4192
  • PE 86.2621
  • Debt/Assets 0.1
  • DivYield 0
  • ROE 0.016

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade OMCL Wells Fargo Equal Weight Overweight -- $35 May 14, 2025

News

Omnicell Gains 41.6% in a Year: What's Driving the Stock?
OMCL
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive

OMCL's shares rise on the back of its XT Amplify program gaining market acceptance with its offerings. However, the unfavorable macroeconomic scenario is concerning.

Read More
image for news Omnicell Gains 41.6% in a Year: What's Driving the Stock?
Omnicell (OMCL) Upgraded to Buy: What Does It Mean for the Stock?
OMCL
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive

Omnicell (OMCL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news Omnicell (OMCL) Upgraded to Buy: What Does It Mean for the Stock?
Omnicell Q4 Earnings: Ignore The Short-Term Noise
OMCL
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Positive

Omnicell's Q4 2024 earnings showed strong service revenue growth, despite soft overall revenue guidance, highlighting the service business as the key value driver. My updated DCF analysis yields a price target of $64.05, representing a 54% upside, and I raise my rating from buy to strong buy. The service business has grown from 6% to 22% of revenue since 2020, outpacing industry growth and improving margins, indicating long-term value.

Read More
image for news Omnicell Q4 Earnings: Ignore The Short-Term Noise

About Omnicell, Inc. (OMCL)

  • IPO Date 2001-08-09
  • Website https://www.omnicell.com
  • Industry Medical - Healthcare Information Services
  • CEO Randall A. Lipps
  • Employees 3620
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.